An Overview of ABT-199 for the Treatment of CLL
Jennifer Brown, MD, PhD, Director, Chronic Lymphocytic Leukemia Center, Dana-Farber Cancer Institute, Assistant Professor of Medicine, Harvard Medical School, discusses the Bcl-2 inhibitor ABT-199 for the treatment of patients with CLL.
Clinical Pearls
Jennifer Brown, MD, PhD, Director, Chronic Lymphocytic Leukemia Center, Dana-Farber Cancer Institute, Assistant Professor of Medicine, Harvard Medical School, discusses the Bcl-2 inhibitor ABT-199 for the treatment of patients with chronic lymphocytic leukemia (CLL).
- ABT-263 demonstrated significant activity in CLL, though caused thrombocytopenia
- ABT-199 has not had thrombocytopenia issues, but is so potent that it has had problems with tumor lysis
- ABT-199 demonstrated an 80-85% nodal response in an ongoing phase I trial (52 patients)
- All 52 patients in the trial experienced a 50% reduction in lymphocyte count
- ABT-199 has demonstrated efficacy in patients with a 17p deletion and may clear bone marrow more effectively than kinase inhibitors
Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond
March 21st 2025Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.
Read More
